EWNYSEOrthopedic, Prosthetic & Surgical Appliances & SuppliesFiscal year ends December 31
Edwards Lifesciences Corp
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 4, 2026
$87.22+0.62 (+0.72%)
Close on Oct 19, 2026
- Market cap
- $50.38B
- P/E (TTM)
- 50.1
- Dividend yield
- –
Share price
+$12.58 (+16.85%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Earnings
Edwards Lifesciences Corp grew revenue 14.6% to $6.51B over the twelve months to Jun 30, 2026. Operating income fell 1.4% to $1.45B, moving the operating margin from 25.8% to 22.3%. Free cash flow was $1.43B, up 143.9% from a year earlier.
Revenue
$6.51B
+14.6% vs. a year earlier
Operating income
$1.45B
-1.4% vs. a year earlier
Free cash flow
$1.43B
+143.9% vs. a year earlier
EPS, diluted
$1.74
-75.0% vs. a year earlier
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $50.38B
- P/E ratio
- 50.1
- Price to sales
- 7.74
- Price to book
- 4.74
- Dividend yield
- –
- Free cash flow yield
- 2.85%
Fundamentals
- Revenue
- $6.51B
- Net income
- $1.00B
- EPS, diluted
- $1.74
- Free cash flow
- $1.43B
- Book value per share
- $18.38
- Diluted shares
- 578M
Fifteen years at a glance
Fiscal years 2011 to 2025 and trailing twelve months, USD
Revenue
$6.51B+14.6% YoY
Gross profit
$5.07B+13.0% YoY
Operating income
$1.45B-1.4% YoY
Net income
$1.00B-75.8% YoY
EPS, diluted
$1.74-75.0% YoY
Free cash flow
$1.43B+143.9% YoY
Reported periodTrailing twelve months